Journal article
New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis
HJ Hugo, C Saunders, RG Ramsay, EW Thompson
Journal of Mammary Gland Biology and Neoplasia | Published : 2015
Abstract
The medicinal use of aspirin stretches back to ancient times, before it was manufactured in its pure form in the late 19th century. Its accepted mechanistic target, cyclooxygenase (COX), was discovered in the 1970s and since this landmark discovery, the therapeutic application of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has increased dramatically. The most significant benefits of NSAIDs are in conditions involving chronic inflammation (CI). Given the recognized role of CI in cancer development, the use of long-term NSAID treatment in the prevention of cancer is an enticing possibility. COX-2 is a key driver of CI, and here we review COX-2 expression as a predictor of ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
We thank Dr Kara Britt (Peter MacCallum Cancer Centre, VIC) for critiquing the manuscript. EWT was supported in part by the EMPathy National Collaborative Research Program funded by the National Breast Cancer Foundation, Australia, and National Health and Medical Research Council (NHMRC) Project Grant 1027527, CS by the Raine Foundation at the University of Western Australia, and RGR by the NHMRC. This study benefited from support by the Victorian Government's Operational Infrastructure Support Program to St. Vincent's Institute and the Peter MacCallum Cancer Institute.